Loading…
Clinical-stage cancer drug developer using stabilized helical peptides (Helicons) to reach hard targets inside cells; lead drug zolucatetide blocks beta-catenin.
Clinical-stage cancer drug developer using stabilized helical peptides (Helicons) to reach hard targets inside cells; lead drug zolucatetide blocks beta-catenin.
With no approved product, it is funded by investor money and partner payments, chiefly a May 2026 deal with Regeneron on antibody-Helicon conjugates, antibodies that carry a Helicon in place of a toxic payload, with upfront and milestone fees. It listed on Nasdaq in June 2026. Value rests on zolucatetide's desmoid-tumor results.
Moat: narrow (IP / patents, process know-how). Proprietary Helicon peptide platform; only one drug in the clinic so far, so the edge is unproven.
Headquarters: Cambridge, Massachusetts, US · Founded: 2015
Size Parabilis Medicines (PBLS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.52B, the 1428th largest of 3,117 United States companies the cockpit tracks. Shares closed at $28.53 on 6 Nov 2026.
Short interest Short interest is 7.6% of the free float (15 Oct 2026).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$2.50M | -$2.11M |
| EBITDA | n/a | -$150M | -$124M |
| Net income | n/a | -$146M | -$118M |
| Free cash flow | n/a | -$124M | -$105M |
| Capital expenditure | n/a | $306,000 | $879,000 |
| Total debt | $47.5M | $58.7M | $66.2M |
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Parabilis Medicines PBLS | $3.52B | n/a | n/a | n/a | n/a | n/a |
| Arvinas ARVN | $420M | -37% | -12% | -10% | n/a | n/a |
| Kymera Therapeutics KYMR | $11.2B | +53% | +134% | -396% | 101.2× | n/a |
| Revolution Medicines RVMD | $41.2B | +36% | n/a | n/a | n/a | n/a |
| Merck KGaA MRK.DE | $72.5B | +23% | 0% | 20% | 3.6× | 7.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PBLS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.6% | +2.8% | 11th highest of 21 |
| Distance from 52-week high | -32.9% | -22.0% | 4th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 3.1× | -2.2% | +12.0% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 12.8× | 20.5% | +98.4% |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 2.7× | -2.8% | +10.6% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 1.8× | -4.5% | -1.0% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 3.7× | 15.2% | +61.4% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 2.4× | 16.7% | +19.4% |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | 4.6× | 31.9% | +159.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 3.8× | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.69B | -11% | -10% | 19% | 2.3× | -7.7% | +2.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.35B | +19% | +26% | 13% | 8.9× | 56.9% | +4.2% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 2.8× | 6.3% | +4.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 0.6× | -5.3% | +7.8% |
| China National Medicines 600511.SS | China | $3.31B | +2% | +3% | 4% | 0.3× | -9.8% | +5.4% |
| China Medical System 0867.HK | Hong Kong | $3.30B | -16% | +15% | 20% | 2.1× | 2.9% | +2.7% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.28B | +39% | +45% | 36% | 19.3× | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.23B | +72% | -63% | -1,781% | 99.3× | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 1.9× | -5.2% | +3.2% |